J Neuroimmunol 2002 Mar;124(1-2):101-5
Mann MB, Wu S, Rostamkhani M, Tourtellotte W, MacMurray JP, Comings DE.
Department of Medical Genetics, City of Hope Medical Center, Duarte, CA, USA
Phenylethanolamine N-methyltransferase (PNMT), the terminal enzyme of the catecholamine biosynthesis pathway, catalyzes the conversion of norepinephrine (NE) to epinephrine (EPI).
PNMT is a candidate gene for multiple sclerosis (MS) for two reasons.
PNMT is known to map to a region identified in two genome screens for MS and it directly regulates the amounts of NE and EPI, both of which play a significant role in the modulation of the innate immune response.
The frequencies of two promoter polymorphisms of the PNMT gene showed genetic association in a case-control study of 108 patients with MS and 774 ethnically and age-matched control subjects.
In subjects with MS, significant differences in the frequency of the GG genotype at the G-387A marker and the AA genotype at the G-182A marker were observed.
Additionally, when both markers were combined and evaluated, highly significant differences between the polymorphism distributions in patients with MS and control subjects were detected.
The data suggest that these promoter polymorphisms of the PNMT gene, both independently and cumulatively, show association with MS.